David Kuo, MD
Internal Medicine · Salt Lake City, UTNPI 1508881640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 495 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 495 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$803
- Lilly USA, LLC$757
- Boehringer Ingelheim$721
- AbbVie$617
- Amgen$587
- Sanofi-aventis U.S. LLC$327
- plus $4K from 43 others
What the payments were for
- Food & beverage$7,960100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,960 in reported general payments places this provider in the 90th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $68,280 |
| TrulicityDulaglutide | 60 | $60,757 |
| OzempicSemaglutide | 47 | $54,948 |
| MounjaroTirzepatide | 39 | $40,340 |
| XareltoRivaroxaban | 23 | $36,203 |
| JardianceEmpagliflozin | 19 | $26,867 |
| JanuviaSitagliptin Phosphate | 15 | $21,872 |
| MyrbetriqMirabegron | 14 | $19,375 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $9,798 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,909 |
| Arnuity ElliptaFluticasone Furoate | 16 | $6,493 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,803 |
| Levothyroxine Sodium | 418 | $4,896 |
| Omeprazole | 287 | $4,496 |
| Dexlansoprazole DrDexlansoprazole | 14 | $4,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $757 | $101,09799 claims |
| PfizerEliquis | $143 | $68,28059 claims |
| Novo NordiskOzempic | $143 | $54,94847 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $721 | $40,57942 claims |
| Johnson & JohnsonXarelto | $141 | $36,20323 claims |
| MerckJanuvia, Janumet | $803 | $31,67028 claims |
| Astellas Pharma US IncMyrbetriq | $304 | $19,37514 claims |
| GSKArnuity Ellipta | $192 | $6,49316 claims |
| AbbVieSynthroid | $617 | $2,34039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Salt Lake City
- Willard DereSalt Lake City$4.7M
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Gerald GleichSalt Lake City$22K
- Brian HornerSalt Lake City$21K
- Rachel HessSalt Lake City$18K
- Linda VennerSalt Lake City$8K
- Evan DaughertySalt Lake City$6K
- Margaret LuntSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.